NorstellaLinQ dataset achieves highest scores on data quality for claims backbone real world data (RWD) use cases and is now available to Atropos Evidence Network members
Today, Atropos Health announces the availability of an initial dataset from NorstellaLinQ on the Atropos Evidence Network, the largest federated data network in healthcare with over 300M patient records. This furthers the strategic partnership between Atropos Health and Norstella, one of the largest global pharma intelligence solution providers, redefining speed to insight from real-world data (RWD) for the life sciences industry.
Atropos Evidence Network members can now benefit from this additional dataset, with more to follow, when they use ChatRWD® and the Green Button™ to ask clinical questions. The Atropos Evidence Network continues to be the data source of choice for life sciences and health system leaders for its breadth of applications–including research and development, clinical trial recruitment, physician targeting, market sizing, clinical trial design, site selection, patient recruitment, brand positioning, market sizing, HEOR and epidemiological insights, commercial targeting, provider engagement, shared decision making, and more. NorstellaLinQ is the biopharma industry’s first fully integrated data asset combining both RWD–including open and closed claims, lab results and structured and unstructured electronic medical records (EMR)–with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data.
When evaluated by Atropos Health’s independent Real World Data Score ® (RWDS) methodology, this dataset scores in the top percentile, indicating it as a fit to answer challenging questions across commercialization, HEOR, and R&D use cases, as evidenced by the high RWFS.